Diprogenta is a fixed-dose combination of betamethasone dipropionate and gentamicin sulfate, two active ingredients paired in a single topical dermatological preparation for the management of inflammatory skin conditions complicated by, or at risk of, bacterial infection. Combination products of this kind formalise a long-standing co-prescribing pattern in dermatology, where a potent topical corticosteroid and a topical antibiotic are often used together on the same lesion.
Betamethasone dipropionate falls within the topical glucocorticoid category, contributing anti-inflammatory, antiallergic, and antipruritic action to the formulation. Gentamicin sulfate is classified as a local antibacterial with a wide spectrum of activity. Together, the two ingredients address the registered indications listed for Diprogenta — including dermatitis, eczema, atopic dermatitis, seborrheic dermatitis, neurodermatitis, psoriasis, jock itch, and empeines — at the level of skin conditions where inflammation and possible bacterial involvement coexist.
Diprogenta is registered in 24 countries, with a footprint that spans Latin America, Central and Southeastern Europe, and parts of Asia. Representative markets include Brazil, Germany, Indonesia, Poland, Colombia, and Israel. Travellers and expatriates moving between these regions may encounter the same brand on local pharmacy shelves, though packaging, pack sizes, and prescription pathways vary from one regulator to another.
Combination dermatological products vary across countries even more than single-ingredient corticosteroids, both in the specific antibiotic paired with the steroid and in the strength of the corticosteroid component. A pharmacist in the destination country can identify whether a comparable corticosteroid-plus-antibiotic preparation is available locally. As with any prescription topical medication, the choice to start, continue, or substitute Diprogenta is best made together with a healthcare provider who knows the skin condition being treated.
